

02 January 2026

CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares

CVS announces that on 31 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

Date of purchase:	31/12/2025
Aggregate number of Ordinary Shares purchased:	4,554
Lowest price paid per share (GBP):	1,266.00
Highest price paid per share (GBP):	1,278.00
Volume weighted average price paid per share (GBP):	1,273.59

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,706,719 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,706,719 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 1,034,064 Ordinary Shares in aggregate at a weighted average price of 1,221.27 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:

Number of Ordinary Shares purchased	Transaction price (GBP share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
70	1266	31/12/2025 10:08:21	1361977762912325	XLON
44	1266	31/12/2025 10:26:31	1361977762912807	XLON
1	1266	31/12/2025 10:26:31	1361977762912808	XLON
10	1266	31/12/2025 10:26:31	1361977762912809	XLON
6	1266	31/12/2025 10:26:31	1361977762912810	XLON
19	1266	31/12/2025 10:26:31	1361977762912811	XLON
6	1266	31/12/2025 10:26:32	1361977762912812	XLON
281	1268	31/12/2025 10:39:29	1361977762913259	XLON
25	1266	31/12/2025 10:39:29	1361977762913260	XLON
106	1268	31/12/2025 10:39:29	1361977762913261	XLON
111	1266	31/12/2025 10:39:32	1361977762913262	XLON
32	1268	31/12/2025 10:50:04	1361977762913570	XLON
9	1268	31/12/2025 10:50:04	1361977762913571	XLON
11	1268	31/12/2025 10:50:04	1361977762913572	XLON
276	1272	31/12/2025 10:59:24	1361977762913854	XLON
96	1272	31/12/2025 10:59:24	1361977762913857	XLON

85	1268	11/14/2025 11:14:47	1361977762914340	XLON
204	1276	31/12/2025 11:23:24	1361977762914655	XLON
191	1274	31/12/2025 11:24:40	1361977762914690	XLON
40	1276	31/12/2025 11:29:31	1361977762914855	XLON
115	1276	31/12/2025 11:29:31	1361977762914856	XLON
483	1270	31/12/2025 11:43:40	1361977762915573	XLON
553	1276	31/12/2025 11:50:04	1361977762915810	XLON
560	1276	31/12/2025 11:50:04	1361977762915813	XLON
78	1276	31/12/2025 11:56:01	1361977762916089	XLON
154	1276	31/12/2025 12:01:30	1361977762916311	XLON
231	1276	31/12/2025 12:03:15	1361977762916359	XLON
135	1276	31/12/2025 12:03:15	1361977762916360	XLON
178	1276	31/12/2025 12:05:10	1361977762916425	XLON
158	1278	31/12/2025 12:11:22	1361977762916728	XLON
286	1278	31/12/2025 12:15:34	1361977762916940	XLON

Contacts

CVS Group plc

Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations

via Camarco

Peel Hunt LLP (Nominated Adviser & Joint Broker)
Christopher Golden / James Steel / Andrew Clark

+44 (0)20 7418 8900

Berenberg (Joint Broker)

Toby Flaux / Michael Burke / Mio Bonser / Brooke Harris-Lowing

+44 (0)20 3207 7800

Camarco (Financial PR)

Ginny Pulbrook
Letaba Rimell
Tilly Butcher

cvsg@camarco.co.uk

+44 (0)7961 315 138

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSWPGGUPUPAGCG